Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
The patient received the third dose of Vivotif three days after first dose and the fourth dose five days after first dose; Case reference number US-BN-2025-001353 is a spontaneous case initially received from a nurse via Communications (reference number: USBAV25-1908) on 04-Aug-2025 and concerns an 18-year-old male patient. The patient's medical history and concomitant medication details were not provided. On 30-Jul-2025, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose, orally, for typhoid immunization. On 01-Aug-2025, two days after the first dose of Vivotif, the patient took the second dose of Vivotif (batch number: unknown) at an unknown dose, orally. On 02-Aug-2025, three days after the first dose of Vivotif, the patient received the third dose of Vivotif (batch number: unknown) at an unknown dose, orally. As reported, there were not 48 hours between dose two and three (explicitly coded as 'inappropriate schedule of vaccine administered') On 04-Aug-2025, five days after the first dose of Vivotif, the patient received the fourth and final dose of Vivotif (batch number: unknown) at unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. No additional information was provided.; Reporter's Comments: An 18-year-old male patient received the third and the fourth dose of Vivotif for typhoid immunization on the days 3 and 5 after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An 18-year-old male patient received the third and the fourth dose of Vivotif for typhoid immunization on the days 3 and 5 after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None